Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 25;10(7):e28468.
doi: 10.1016/j.heliyon.2024.e28468. eCollection 2024 Apr 15.

Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment

Feryal Savari  1 , Seyed Ali Mard  2
Affiliations
Review

Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment

Feryal Savari et al. Heliyon. .

Erratum in

Abstract

Non-alcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease and a progressive and chronic liver disorder with a significant risk for the development of liver-related morbidity and mortality. The complex and multifaceted pathophysiology of NASH makes its management challenging. Early identification of symptoms and management of patients through lifestyle modification is essential to prevent the development of advanced liver disease. Despite the increasing prevalence of NASH, there is no FDA-approved treatment for this disease. Currently, medications targeting metabolic disease risk factors and some antifibrotic medications are used for NASH patients but are not sufficiently effective. The beneficial effects of different drugs and phytochemicals represent new avenues for the development of safer and more effective treatments for NASH. In this review, different risk factors, clinical symptoms, diagnostic methods of NASH, and current treatment strategies for the management of patients with NASH are reviewed.

Keywords: Diagnosis; MASLD; Management; NAFLD; NASH; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
The risk factors that may induce non-alcoholic fatty liver disease (NAFLD) in the liver of patients.
See this image and copyright information in PMC

References

    1. Huang T., Behary J., Zekry A. Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern. Med. J. 2020;50(9):1038–1047. - PubMed
    1. Younossi Z.M., Tampi R., Priyadarshini M., Nader F., Younossi I.M., Racila A. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States. Hepatology. 2019;69(2):564–572. - PubMed
    1. Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. - PubMed
    1. Vickers N.J. Animal communication: when i'm calling you, will you answer too? Curr. Biol. 2017;27(14):R713–R715. - PubMed
    1. Younossi Z.M., Golabi P., Paik J.M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. - PMC - PubMed

LinkOut - more resources